异丙托溴铵雾化吸入为主三联治疗慢阻肺急性加重期疗效观察

Clinical Efficacy of Triple Therapy Based on Ipratropium Bromide Inhalation in the Treatment of AECOPD

目的:探讨异丙托溴铵雾化吸入为主三联治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及安全性。方法:AECOPD患者150例随机分为两组各75例对照组给予布地奈德+沙丁胺醇雾化吸入,观察组在此基础上加用异丙托溴铵雾化吸入治疗。比较两组患者临床疗效、治疗前后呼吸困难评分、肺功能指标水平、血气分析指标水平及药品不良反应发生率等指标。结果:观察组临床总有效率显著优于对照组(P<0.05)。两组患者治疗后呼吸困难评分、肺功能指标及血气分析指标均较治疗前有显著改善(P<0.05)沮观察组患者上述指标均显著优于对照组(P<0.05)。两组药品不良反应发生率比较差异无统计学意义(P>0.05)。结论:异丙托溴铵雾化吸入为主三联治疗AECOPD患者可有效缓解临床症状体征,改善肺部通气功能提高临床疗效,且未增加不良反应发生风险。

Objective： To investigate the clinical effects and safety of triple therapy based on ipratropium bromide inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary diseases （AECOPD）. Methods： Totally 150 patients with acute exac- erbation of AECOPD were randomly divided into control group （75 patients） treated with budesonide combined with salbutamol by in- halation, and treatment group （75 patients） treated with ipratropium bromide inhalation additionally. The clinical effects, dyspnea score, pulmonary function index and blood gas analysis index before and after the treatment and the incidence of adverse reactions of the two groups were compared. Results： The clinical effects of the treatment group was significantly better than that of the control group （ P 〈 0.05 ）. The dyspnea score, pulmonary function index in and blood gas analysis index in the two groups after the treatment were significantly better than those before the treatment（ P 〈0.05 ）, and the improvement of the treatment group was significantly better than that of control group （P 〈 0.05 ）. There was no significant difference in the incidence of adverse reactions between the two groups（P 〉 0.05 ）. Conclusion： Triple therapy including ipratropium bromide inhalation in the treatment of acute exacerbation of AECOPD can effectively alleviate clinical symptoms and signs and improve the lung ventilation function without increased risk of adverse reactions.